Unicycive Therapeutics (UNCY) Competitor Comparison
We are evaluating the key criteria listed to compare Unicycive Therapeutics (UNCY) against its competitors in the Biotechnology industry.
Market Capitalization
291 / 368Gross Profits
0 / 278Total Revenue
245 / 300EBITDA
82 / 337Free Cashflow
50 / 352Quick Ratio
329 / 357Earnings per Share
143 / 359Dividend yield
0 / 5Total Cash
310 / 358Performance 3 years
260 / 368Performance 5 years
255 / 368Performance 10 years
224 / 368Linearity 3 years
201 / 367Linearity 5 years
235 / 367Linearity 10 years
185 / 368Total Rank
47 / 368Dividend Rank
294 / 368Valuation Rank
47 / 368Piotroski Rank
175 / 368Muliplier Rank
118 / 368Quick Ratio - UNCY ranking 329 / 357
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.